Global DNA Repair Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for DNA Repair Drugs Market is presumed to reach the market size of nearly USD 24.79 Billion by 2032 from USD 7.02 Billion in 2023 with a CAGR of 15.05% under the study period 2024-2032.

DNA damage causes alteration of structure in genetic material. It causes the inclusion of deficiencies and abnormalities in the DNA structure, which leads to mutations in the DNA. The mutations take place in the genes coding for essential proteins or enzymes. Thus DNA damage hampers the proper functioning and performance of the DNA resulting in the development of genetic disorders. However, the human body is capable of repairing damaged DNA sequences. DNA repairing is a combination of processes altogether that includes identification of cells where the mutation has occurred and the correction of DNA molecules that are involved in the encoding genome. Certain drugs such as poly ADP ribose polymerase (PARP) inhibitors are used to enhance the body's DNA repairing mechanism. DNA repair drugs support the treatments related to DNA damage and genetic abnormalities.

MARKET DYNAMICS

The prevalence of cancer is rising rapidly across the globe. Mutations in the genes cause uncontrolled cell growth leading to cancer. Cancer is one of the major diseases responsible for a large number of deaths across the globe. The increasing prevalence of cancer is propelling the global DNA repair drugs market. Furthermore, the growing adoption of advanced next-generation technologies to treat cancer and other genetic diseases is fueling demand. The key manufacturers are investing in R & D on a large scale to find effective drug solutions to support the DNA repair mechanism. The strategies acquired by key market players are propelling the global market. COVID-19 pandemic is supporting the R & D in drug development that is likely to enhance the global DNA repair drugs market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of DNA Repair Drugs. The growth and trends of DNA Repair Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the DNA Repair Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Type

Talazoparib
Olaparib
Niraparib
Rucaparib
Other Drug Types

By Application

Breast Cancer
Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer
Other Applications

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Other Distribution Channels

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the DNA Repair Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the DNA Repair Drugs market include AstraZeneca Plc, Onxeo, Johnson & Johnson, FoRx Therapeutics, AbbVie, Artios Pharma Limited, Pfizer Inc., Breakpoint Therapeutics, Luciole Pharmaceuticals, Merck KGaA, ClovisOncology Inc., GlaxoSmithKline Plc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11212424

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. DNA REPAIR DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Type
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL DNA REPAIR DRUGS MARKET ANALYSIS BY DRUG TYPE

5.1. Overview By Drug Type
5.2. Historical and Forecast Data
5.3. Analysis By Drug Type
5.4. Talazoparib Historic and Forecast Sales By Regions
5.5. Olaparib Historic and Forecast Sales By Regions
5.6. Niraparib Historic and Forecast Sales By Regions
5.7. Rucaparib Historic and Forecast Sales By Regions
5.8. Other Drug Types Historic and Forecast Sales By Regions

6. GLOBAL DNA REPAIR DRUGS MARKET ANALYSIS BY APPLICATION

6.1. Overview By Application
6.2. Historical and Forecast Data
6.3. Analysis By Application
6.4. Breast Cancer Historic and Forecast Sales By Regions
6.5. Ovarian Cancer Historic and Forecast Sales By Regions
6.6. Peritoneal Cancer Historic and Forecast Sales By Regions
6.7. Fallopian Tube Cancer Historic and Forecast Sales By Regions
6.8. Other Applications Historic and Forecast Sales By Regions

7. GLOBAL DNA REPAIR DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1. Overview By Distribution Channel
7.2. Historical and Forecast Data
7.3. Analysis By Distribution Channel
7.4. Hospital Pharmacies Historic and Forecast Sales By Regions
7.5. Retail Pharmacies Historic and Forecast Sales By Regions
7.6. Other Distribution Channels Historic and Forecast Sales By Regions

8. GLOBAL DNA REPAIR DRUGS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE DNA REPAIR DRUGS COMPANIES

9.1. DNA Repair Drugs Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF DNA REPAIR DRUGS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. AstraZeneca Plc
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Onxeo
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Johnson & Johnson
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. FoRx Therapeutics
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. AbbVie
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. Artios Pharma Limited
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Pfizer Inc.
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Breakpoint Therapeutics
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Luciole Pharmaceuticals
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Merck KGaA
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. ClovisOncology Inc.
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
10.14. GlaxoSmithKline Plc
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies